ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01557400
Recruitment Status : Active, not recruiting
First Posted : March 19, 2012
Last Update Posted : January 18, 2018
Sponsor:
Information provided by (Responsible Party):
PTC Therapeutics

March 15, 2012
March 19, 2012
January 18, 2018
May 2012
March 2018   (Final data collection date for primary outcome measure)
Long term Safety and Tolerability of Ataluren. [ Time Frame: 336 weeks ]
The primary objective of this study is to assess the long-term safety and tolerability of 10, 10, 20 mg/kg ataluren in patients with nmDBMD who had prior exposure to ataluren in a PTC-sponsored clinical trial.Safety profile characterized by type, frequency, severity, timing, and relationship to Ataluren of any adverse events or laboratory abnormalities.
Safety and Tolerability [ Time Frame: 48 weeks ]
The safety profile of ataluren will be characterized by type, frequency, severity, timing, and relationship to ataluren of any adverse events or laboratory abnormalities
Complete list of historical versions of study NCT01557400 on ClinicalTrials.gov Archive Site
Not Provided
  • Change from baseline in 6MWD as measured by the 6MWT (in ambulatory patients) [ Time Frame: 48 weeks ]
  • Change from baseline in subject and parent/caregiver-reported activities of daily living, as measured by the Egen Klassifikation (EK) scale (in nonambulatory patients) [ Time Frame: 48 weeks ]
  • Change from baseline in timed function tests (in ambulatory patients) [ Time Frame: 48 weeks ]
  • Change from baseline in pulmonary function as measured by spirometry (in nonambulatory patients) [ Time Frame: 48 weeks ]
  • Change from baseline in physical function as measured by the North Star Ambulatory Assessment (in ambulatory patients) [ Time Frame: 48 weeks ]
  • Changes in patient and/or parent/caregiver reports of disease status as measured by a standardized survey administered by site personnel [ Time Frame: 48 weeks ]
Not Provided
Not Provided
 
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada
An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy
Duchenne/Becker muscular dystrophy (DBMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of DBMD in approximately 10-15% of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study comprises a Phase 3, open-label study of ataluren in patients with nmDBMD who previously received ataluren at an investigator site in a prior PTC-sponsored clinical study. A separate open-label study (PTC124-GD-016-DMD) is being conducted for nmDBMD patients who previously received ataluren at an investigator site in the United States (US).

All participating sites must have had at least 1 patient that received ataluren treatment in a prior PTC-sponsored clinical study in DBMD. It is planned that up to ~96 patients will be enrolled.

Subjects will receive ataluren 3 times per day (TID) at respective morning, midday, and evening doses of 10 mg/kg, 10 mg/kg, and 20 mg/kg, for approximately 336 weeks. Study assessments will be performed at clinic visits during screening, on the first day of ataluren dosing, and then every48 weeks during the ataluren treatment period, except for weight, which will be measured every 24 weeks at a primary care physician (PCP). No measures of efficacy will be captured.

Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Duchenne Muscular Dystrophy
  • Becker Muscular Dystrophy
  • Dystrophinopathy
Drug: Ataluren
Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
Other Name: PTC124
Experimental: Ataluren
Ataluren
Intervention: Drug: Ataluren

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
95
96
March 2018
March 2018   (Final data collection date for primary outcome measure)
  1. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.

    Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible Institutional Review Board/Independent Ethics Committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the subject should be followed.

  2. History of exposure to ataluren in a prior PTC study in nmDBMD . Note: Patients are considered eligible only if they received ataluren during their participation in one or more prior PTC-sponsored studies of ataluren in nmDBMD. Note: Subjects who have participated in a prior or ongoing PTC study with ataluren in nmDBMD at a trial site in the US or Canada, but reside outside of the US and Canada, may be eligible for this study (with the approval of the PTC Therapeutics Medical Monitor).
  3. Male sex.
  4. In patients who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during ataluren administration and the 6-week follow-up period.
  5. Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions. Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.

Exclusion Criteria:

  1. Exposure to another investigational drug within 1 month prior to start of study treatment.
  2. Eligibility for another ataluren clinical trial that is actively enrolling study participants.
  3. Known hypersensitivity to any of the ingredients or excipients of ataluren (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127 [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, Cab-O-Sil® M5P [colloidal silica], magnesium stearate).
  4. Ongoing use of the following medications:

    1. Coumarin-based anticoagulants (eg, warfarin), phenytoin, tolbutamide, or paclitaxel.
    2. Systemic aminoglycoside therapy
  5. Ongoing uncontrolled medical/surgical condition, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient or make it unlikely that follow-up would be completed.
Sexes Eligible for Study: Male
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Canada,   France,   Germany,   Israel,   Italy,   Spain,   Sweden,   United Kingdom
 
 
NCT01557400
PTC124-GD-019-DMD
No
Not Provided
Plan to Share IPD: No
PTC Therapeutics
PTC Therapeutics
Not Provided
Study Director: Edward O'Mara, MD PTC Therapeutics
PTC Therapeutics
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP